An ongoing dialogue on HIV/AIDS, infectious diseases,
April 23rd, 2008
Antiretrovirals in the Pipeline: And Then There Were … None?
The flurry of drug approvals that began in 2005 with tipranavir – followed rapidly by darunavir, maraviroc, raltegravir, and most recently etravirine – has been nothing short of astounding. Every experienced HIV clinician now has many patients who are on successful (read: suppressive) treatment for the first time ever. The Vancouver HIV program — wonderfully called “Centre for Excellence” (why couldn’t our clinic have chosen that name?) — reports that the incidence of drug resistance is declining “drastically.” And their experience is not unique, even though their “excellence” moniker might be.
All good news, right? Well, mostly.
The only downside to all this successful treatment is that the incentive for new drug development must be at an all-time low, especially for antiretrovirals with activity against highly resistant viruses. Unless there’s something flying below the radar, I can’t think of a single new drug likely to gain FDA approval in the next 2-3 years that will provide an effective option to people with no options – in other words, for those unlucky few who don’t have at least two fully active drugs available even with today’s extensive choices.
But how many patients are in this category? I suspect it’s not many: a highly unscientific survey identified three — yes, three — such individuals among the 1200 or so cared for in our clinics. The pie chart of virologic outcomes for people being treated for HIV now looks like this: undetectable virus (largest piece), detectable virus but patient not taking meds for any number of reasons (2nd largest piece), and finally, detectable virus, compliant patient, but no treatment options (just a sliver).
So how many patients with “no options” do you care for? What do you do for them and tell them?
Categories: Health Care, HIV, Infectious Diseases, Patient Care
Tags: antiretrovirals, ART, drug development, HIV, resistance
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
Comments are closed.
Paul E. Sax, MD
NEJM Journal Watch
Biography | Disclosures | Summaries
Learn more about HIV and ID Observations.
Follow HIV and ID Observations Posts via Email
- Types of HIV Papers — A Quick Guide
- As the Public Health Emergency Comes to an End, How Are We Feeling About This?
- The Legacy of a Disappointing HIV Clinical Trial — Does It Still Apply to HIV Today?
- Continued Activity of NRTIs Despite Resistance Is a Real Thing
- What is the Future of HIV Primary Care?
- ID Cartoon Caption Contest (125)
- ID Cartoon Caption Contest #2 Winner — and a New Contest for the Holidays (92)
- Dear Nation — A Series of Apologies on COVID-19 (80)
- How to Induce Rage in a Doctor (77)
- IDSA’s COVID-19 Treatment Guidelines Highlight Difficulty of “Don’t Just Do Something, Stand There” (74)
NEJM Journal Watch — Recent Infectious Disease Articles
- Fosmanogepix Shows Promise for Managing Disseminated Fusarium Infection
- Observations from ID and Beyond: The Legacy of a Disappointing HIV Clinical Trial — Does It Still Apply to HIV Today?
- Factors Influencing ART Outcomes in U.S. Women Living with HIV
- Recent COVID-19 Can Confound HIV Test Results
- Bringing Treatment from Pets to People: Emodepside Activity Against Whipworm and Hookworm Infections
- 3tc Abacavir AIDS antibiotics antiretroviral therapy ART atazanavir baseball CDC C diff COVID-19 CROI darunavir dolutegravir elvitegravir etravirine FDA HCV hepatitis C HIV HIV cure HIV testing ID fellowship ID Learning Unit Infectious Diseases influenza Link-o-Rama lyme disease MRSA PEP Policy PrEP prevention primary care raltegravir Really Rapid Review resistance Retrovirus Conference rilpivirine sofosbuvir TDF/FTC tenofovir Thanksgiving vaccines zoster